Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 282

Similar articles for PubMed (Select 21509346)

1.

Treatment patterns of anti-TNF agents in Italy: an observational study.

Punzi L, Matucci Cerinic M, Cantini F, Bagnato G, Fiocco U, Ferri C, Bombardieri S.

Reumatismo. 2011 Mar;63(1):18-28.

PMID:
21509346
2.

Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.

Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.

J Rheumatol. 2011 Jul;38(7):1273-81. doi: 10.3899/jrheum.101142. Epub 2011 May 15.

PMID:
21572150
3.

Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.

Carter CT, Changolkar AK, Scott McKenzie R.

J Med Econ. 2012;15(2):332-9. doi: 10.3111/13696998.2011.649325. Epub 2012 Jan 6.

PMID:
22168788
4.

Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.

Ollendorf DA, Klingman D, Hazard E, Ray S.

Clin Ther. 2009 Apr;31(4):825-35. doi: 10.1016/j.clinthera.2009.04.002.

PMID:
19446156
5.

Tumor necrosis factor blocker dose escalation among biologic naïve rheumatoid arthritis patients in commercial managed-care plans in the 2 years following therapy initiation.

Bonafede MM, Gandra SR, Fox KM, Wilson KL.

J Med Econ. 2012;15(4):635-43. doi: 10.3111/13696998.2012.667028. Epub 2012 Mar 1.

PMID:
22332705
6.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Chen YF, Jobanputra P, Barton P, Jowett S, Bryan S, Clark W, Fry-Smith A, Burls A.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. Review.

7.

Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.

Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.

J Manag Care Pharm. 2013 Oct;19(8):621-30.

8.

Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis.

Du Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A; Swiss Clinical Quality Management Physicians.

Arthritis Rheum. 2009 May 15;61(5):560-8. doi: 10.1002/art.24463.

9.

Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.

Oladapo A, Barner JC, Lawson KA, Novak S, Rascati KL, Richards KM, Harrison DJ.

J Manag Care Spec Pharm. 2014 Jul;20(7):657-67.

10.

Differences in biologic dose-escalation, non-biologic and steroid intensification among three anti-TNF agents: evidence from clinical practice.

Moots RJ, Haraoui B, Matucci-Cerinic M, van Riel PL, Kekow J, Schaeverbeke T, Davis A, Tedeschi MA, Freundlich B, Chang DJ, Singh A.

Clin Exp Rheumatol. 2011 Jan-Feb;29(1):26-34. Epub 2011 Feb 23.

PMID:
21345289
11.

Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study.

Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ; British Society for Rheumatology Biologics Register.

Arthritis Rheum. 2007 Jan;56(1):13-20.

12.

Survival of TNF-alpha antagonists in rheumatoid arthritis: a long-term study.

Markatseli TE, Alamanos Y, Saougou I, Voulgari PV, Drosos AA.

Clin Exp Rheumatol. 2012 Jan-Feb;30(1):31-8. Epub 2012 Mar 6.

PMID:
22153557
13.

Efficiency of adalimumab, etanercept and infliximab in rheumatoid arthritis patients: dosing patterns and effectiveness in daily clinical practice.

Ramírez-Herráiz E, Escudero-Vilaplana V, Alañón-Plaza E, Trovato-López N, Herranz-Alonso A, Morell-Baladrón A, Sanjurjo-Sáez M.

Clin Exp Rheumatol. 2013 Jul-Aug;31(4):559-65. Epub 2013 May 27.

PMID:
23710583
14.

Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.

Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.

Ann Rheum Dis. 2009 Apr;68(4):552-7. doi: 10.1136/ard.2007.087130. Epub 2008 May 8.

PMID:
18467515
15.

Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis.

Finckh A, Simard JF, Gabay C, Guerne PA; SCQM physicians.

Ann Rheum Dis. 2006 Jun;65(6):746-52. Epub 2005 Dec 8.

16.

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L.

Arthritis Rheum. 2009 Nov;60(11):3180-9. doi: 10.1002/art.24941.

17.

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.

Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP; British Society for Rheumatology Biologics Register.

Arthritis Res Ther. 2009;11(2):R52. doi: 10.1186/ar2670. Epub 2009 Apr 8.

18.

Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis.

Harrison DJ, Huang X, Globe D.

Am J Health Syst Pharm. 2010 Aug;67(15):1281-7. doi: 10.2146/ajhp090487.

PMID:
20651319
19.

Outcomes of switching anti-TNF drugs in rheumatoid arthritis--a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN).

Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Komulainen R, Koivuniemi R, Yli-Kerttula U, Mali M, Sihvonen S, Krogerus ML, Jukka E, Nyrhinen S, Konttinen YT, Nordström DC.

Clin Rheumatol. 2011 Nov;30(11):1447-54. doi: 10.1007/s10067-011-1779-1. Epub 2011 Jun 7.

PMID:
21644062
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk